Doctors prescribe medications for conditions they weren’t originally designed for because, in many cases, no approved alternative exists, or every approved option has already failed. This practice, known as off-label prescribing, accounts for roughly one in five prescriptions written in the United States, with some estimates placing the figure closer to one in three for commonly used drugs. It is perfectly legal. Once the FDA approves a medication for any single purpose, physicians can prescribe it for any condition they believe it will safely and effectively treat. Quetiapine, for instance, was approved for schizophrenia and bipolar disorder, yet it is now one of the most widely prescribed medications for insomnia — a use the FDA never formally blessed. For families navigating dementia care, this reality hits close to home.
Many of the medications used to manage behavioral symptoms in dementia patients — agitation, sleep disturbances, anxiety — are prescribed off-label because so few drugs have been specifically approved for these purposes. Understanding why doctors make these choices, what evidence supports them, and where the risks lie can help caregivers have more informed conversations with medical teams. This article breaks down the reasons behind off-label prescribing, examines how common it really is, looks at the most frequently prescribed off-label medications, and addresses the safety concerns that every patient and caregiver should know about. The stakes are not trivial. Research published in the Archives of Internal Medicine found that 73 percent of off-label drug uses lacked strong scientific evidence to support them. That does not mean every off-label prescription is reckless — some have decades of clinical experience behind them — but it does mean patients and caregivers need to ask the right questions.
Table of Contents
- What Exactly Is Off-Label Prescribing and Why Do Doctors Do It?
- How Common Is Off-Label Prescribing Across Different Drug Classes?
- Off-Label Medications You or Your Family May Already Be Taking
- How to Evaluate Whether an Off-Label Prescription Is Right for Your Situation
- The Real Risks of Off-Label Prescribing That Patients Should Understand
- What the FDA Actually Regulates and What It Doesn’t
- Where Off-Label Prescribing Is Headed, Especially in Dementia Care
- Conclusion
- Frequently Asked Questions
What Exactly Is Off-Label Prescribing and Why Do Doctors Do It?
Off-label prescribing means using an FDA-approved medication for a condition, patient population, or dosage that was not part of its original approval. The FDA regulates how drugs are marketed, not how doctors prescribe them. So while a pharmaceutical company cannot advertise gabapentin as a treatment for anxiety, a physician who has reviewed the evidence can absolutely write that prescription. The American Medical Association supports this practice on the condition that it is backed by strong medical rationale and sound scientific evidence. There are several straightforward reasons doctors turn to off-label options. Sometimes no FDA-approved drug exists for a patient’s specific condition. Other times, every approved treatment has been tried and failed, leaving off-label use as the next reasonable step.
This is especially common in geriatric and pediatric medicine, where many drugs simply have not been studied in those populations. Any use in an unstudied group is technically off-label, even if it has become standard practice. Clonidine, for example, was approved to treat high blood pressure but is now routinely prescribed off-label for ADHD, opioid withdrawal, migraines, and restless leg syndrome — uses supported by years of clinical observation. Clinical innovation also drives the practice. Physicians often encounter emerging research suggesting a known drug may help with a new condition, but the formal FDA approval process takes years and costs hundreds of millions of dollars. Waiting for that process to finish means withholding a potentially effective treatment. Tricyclic antidepressants were never FDA-approved for neuropathic pain, yet they are now considered a first-line treatment for it — a status earned through clinical experience long before any regulatory body weighed in.
How Common Is Off-Label Prescribing Across Different Drug Classes?
The numbers are striking, and they vary dramatically by drug class. Anticonvulsants lead the pack at 74 percent off-label use, followed by antipsychotics at 60 percent and antibiotics at 41 percent. At the other end of the spectrum, diabetes therapies sit at just 1 percent off-label use. Among individual medications, gabapentin holds the highest proportion of off-label prescriptions at 83 percent, meaning the vast majority of people taking it are using it for something other than epilepsy, its original approved indication. Amitriptyline follows at 81 percent off-label use. For children, the situation is particularly pronounced.
About 19 percent of an estimated 2 billion office visits involved one or more off-label drug orders, frequently for respiratory infections, asthma, or mental health disorders. Pediatric medicine has long relied on off-label prescribing because drug manufacturers have historically had little financial incentive to run clinical trials in children. The result is that pediatricians often must extrapolate from adult data and adjust doses based on weight and clinical experience rather than rigorous pediatric studies. However, frequency should not be confused with safety. The fact that a practice is widespread does not mean it is always well-supported. If your loved one is prescribed a medication off-label — particularly an antipsychotic, which carries a black box warning about increased mortality risk in elderly dementia patients — it is worth asking the prescribing physician what evidence supports that specific use. Not all off-label prescriptions carry the same level of risk, and not all have the same depth of evidence behind them.
Off-Label Medications You or Your Family May Already Be Taking
Many people are taking off-label medications without realizing it, because some of these uses have become so established that they feel like standard medicine. Low-dose aspirin recommended for patients with Type 2 diabetes is technically off-label. Bupropion, marketed as Wellbutrin for depression, is frequently prescribed off-label for smoking cessation and ADHD. Prazosin, a blood pressure medication, has found a second life treating PTSD-related nightmares in veterans — a use driven almost entirely by clinical observation rather than formal trials. In dementia care specifically, the off-label landscape is vast.
Antipsychotics like quetiapine are commonly prescribed to manage agitation and psychosis in dementia patients, despite being approved only for schizophrenia and bipolar disorder. Lithium, approved for bipolar disorder, is prescribed off-label for major depressive disorder, and modafinil, approved for sleep disorders like narcolepsy, is used off-label for depression augmentation — a use supported by a 2013 meta-analysis. These are not fringe practices. They reflect the reality that the FDA approval process cannot keep pace with clinical need. The pattern is consistent: a drug proves useful for something beyond its original scope, clinicians share their experiences, supporting evidence accumulates in medical literature, and eventually the off-label use becomes part of routine clinical practice. The formal approval never comes because no one is willing to spend the money to pursue it.
How to Evaluate Whether an Off-Label Prescription Is Right for Your Situation
When a doctor prescribes something off-label, the first question to ask is straightforward: what is the evidence? There is a meaningful difference between a drug that has been used off-label for 20 years with published studies supporting it and one that a physician is trying based on a hunch or a single case report. Tricyclic antidepressants for nerve pain fall into the first category — well-studied, widely accepted, and recommended by medical guidelines. A newer medication being repurposed based on limited data falls into the second, and that distinction matters. The tradeoff is always between potential benefit and known risk. For a dementia patient experiencing severe agitation that puts them or their caregivers in danger, the risk of an off-label antipsychotic may be justified even though the evidence is imperfect.
For mild sleep difficulty, the calculus looks different, and non-pharmaceutical approaches might deserve a longer trial before reaching for quetiapine. Research from the Information Technology and Innovation Foundation found that replacing off-label drug use with on-label alternatives could reduce per capita medical and work-loss costs by $515, roughly 13 percent. That statistic suggests off-label prescribing sometimes continues even when approved alternatives exist — which is worth investigating with your doctor. Ask the prescriber these specific questions: Is there an FDA-approved medication for this condition that we haven’t tried? What evidence supports this off-label use? What side effects should I watch for that might be different from the drug’s labeled uses? And how will we know if it’s working? These are not confrontational questions. They are the questions any informed patient or caregiver should be asking.
The Real Risks of Off-Label Prescribing That Patients Should Understand
The central concern is this: 80 percent of off-label prescriptions lacked strong scientific evidence backing them. That does not mean they are all harmful, but it does mean the safety net of rigorous clinical trials — the process that catches dangerous side effects before a drug reaches patients — is largely absent. Patients prescribed medications off-label may face higher risks of medication errors, unexpected side effects, and adverse drug reactions simply because the data on that particular use is thin. The opioid crisis offers a grim cautionary tale. Opioids were prescribed off-label for types of pain that did not justify their use, contributing directly to addiction and overdose deaths on a massive scale.
That was not a failure of the concept of off-label prescribing — it was a failure of judgment, incentives, and oversight. But it illustrates what can go wrong when prescribing outpaces evidence. For elderly dementia patients, who are often on multiple medications and more vulnerable to side effects, the margin for error is even smaller. A 2025 survey found that 46.3 percent of Americans support physician discretion for off-label prescribing, while 63 percent expressed safety concerns about off-label Ozempic use specifically. That split captures the public’s ambivalence well: people generally trust their doctors but grow uneasy when a specific case makes the risks feel concrete. For caregivers of dementia patients, the discomfort is amplified by the fact that the patient often cannot advocate for themselves.
What the FDA Actually Regulates and What It Doesn’t
A common misconception is that the FDA controls how doctors prescribe medications. It does not. The FDA regulates drug marketing — what pharmaceutical companies can say about their products. Drug manufacturers are prohibited from promoting off-label uses, even though doctors are free to prescribe them.
This creates an odd dynamic: the company that makes a drug cannot tell doctors about evidence supporting a new use, but the doctor can prescribe it anyway based on published research they find independently. Congressional discussions have explored whether to allow manufacturers to share off-label use data under certain conditions, which could help bridge this gap. The argument in favor is that physicians would benefit from more complete information. The argument against is that pharmaceutical companies have a financial incentive to expand the use of their products, and loosening restrictions could open the door to thinly veiled marketing disguised as education. For now, the regulatory landscape remains unchanged: the FDA acknowledges off-label use, the AMA supports it with caveats, and the responsibility falls largely on individual physicians to stay current with the evidence.
Where Off-Label Prescribing Is Headed, Especially in Dementia Care
The future of off-label prescribing will likely be shaped by two forces pulling in opposite directions. On one side, advances in precision medicine and genetic testing may make it easier to predict which patients will respond to which drugs, potentially making some off-label uses safer and more targeted. On the other side, growing public scrutiny and the lessons of past mistakes — particularly with opioids and antipsychotics in nursing homes — are pushing toward tighter evidence requirements before a drug is used outside its approved indications.
For dementia care, this tension is especially relevant. The pipeline of drugs specifically approved for dementia-related behavioral symptoms remains thin, which means off-label prescribing will continue to be a cornerstone of treatment for the foreseeable future. The most productive path forward for families is not to view off-label prescribing as inherently good or bad, but to insist on transparency — to know when a medication is being used off-label, what evidence supports it, and what the plan is if it does not work.
Conclusion
Off-label prescribing exists because medicine is messier than the regulatory framework that governs it. Diseases do not wait for FDA approval timelines, and patients — particularly those with dementia — often have needs that no approved medication squarely addresses. The practice is legal, common, and in many cases backed by solid clinical experience. But it also operates with less oversight and less evidence than on-label prescribing, which means the burden of diligence shifts more heavily onto prescribers and the families who advocate for patients. The single most important thing a caregiver can do is ask questions.
Know which medications are being prescribed off-label. Understand what evidence exists for that use. Monitor for side effects that may not be well-documented. And do not hesitate to seek a second opinion if something does not feel right. Off-label prescribing is a tool, and like any tool, its value depends entirely on how carefully it is used.
Frequently Asked Questions
Is off-label prescribing legal?
Yes. Once a drug is FDA-approved for any purpose, physicians can legally prescribe it for any condition they deem safe and effective based on their professional judgment. The FDA does not restrict how doctors prescribe after initial approval.
How common is off-label prescribing?
Roughly one in five prescriptions in the U.S. are for off-label use, with some estimates reaching one in three for common drugs. Certain drug classes, like anticonvulsants at 74 percent and antipsychotics at 60 percent, have especially high off-label rates.
Does my doctor have to tell me a prescription is off-label?
There is no universal legal requirement for physicians to disclose off-label use, though the AMA emphasizes that off-label prescribing should be backed by strong medical rationale and scientific evidence. It is always reasonable to ask your doctor whether a medication is being used on-label or off-label.
Are off-label prescriptions covered by insurance?
Coverage varies by insurer and by the specific drug and condition. Some insurers cover well-established off-label uses, while others may deny coverage for uses that lack strong evidence or are not included in drug compendia. Always check with your insurance provider before filling a prescription.
What should I do if I’m concerned about an off-label prescription for a family member with dementia?
Ask the prescribing physician what evidence supports the specific off-label use, whether approved alternatives have been tried, what side effects to monitor, and what the plan is for reassessing the medication over time. You can also request a referral to a geriatric psychiatrist or neurologist for a second opinion.
